Antibody therapeutics that bind cd38
US-2016297888-A1 · Oct 13, 2016 · US
Antibody therapeutics that bind CD38
US9951144B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9951144-B2 |
| Application number | US-201615093773-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 8, 2016 |
| Priority date | Apr 8, 2015 |
| Publication date | Apr 24, 2018 |
| Grant date | Apr 24, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
There is disclosed compositions and methods relating to or derived from anti-CD38 antibodies. More specifically, there is disclosed fully human antibodies that bind CD38, CD38-antibody binding fragments and derivatives of such antibodies, and CD38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
First claim
Opening claim text (preview).
We claim: 1. An isolated fully human anti-CD38 antibody of an IgG class comprising: a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 21; and a light chain variable domain comprising the amino acid sequence of SEQ ID NO. 22. 2. An isolated anti-CD38 fully human antibody fragment comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 21; and a light chain variable domain comprising the amino acid sequence of SEQ ID NO. 22, wherein the fragment is a Fab fragment or a single chain antibody comprising the heavy chain variable domain and the light chain variable domain which are connected by a peptide linker. 3. A method of treating CD38 positive hematological cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of the antibody of claim 1 , such that the cancer is treated. 4. The method of claim 3 , wherein the CD38 positive hematological cancer is selected from the group consisting of non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL), multiple myeloma (MM), B chronic lymphocytic leukemia (B-CLL), B and T acute lymphocytic leukemia (ALL), T cell lymphoma (TCL), acute myeloid leukemia (AML), hairy cell leukemia (HCL), Hodgkin's Lymphoma (HL), and chronic myeloid leukemia (CML).
Assignees
Inventors
Classifications
specific for leukemia · CPC title
Antineoplastic agents · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
comprising antibodies · CPC title
- C07K16/2896Primary
against molecules with a "CD"-designation, not provided for elsewhere · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9951144B2 cover?
- There is disclosed compositions and methods relating to or derived from anti-CD38 antibodies. More specifically, there is disclosed fully human antibodies that bind CD38, CD38-antibody binding fragments and derivatives of such antibodies, and CD38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and deri…
- Who is the assignee on this patent?
- Sorrento Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2896. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).